Caris Life Sciences (CAI) Q3 FY2026 earnings: revenue $275 million, up 27.0% on the year
Caris Life Sciences, Inc. (CAI) reported revenue of $275 million for Q3 FY2026, the quarter ended 30 September 2026, up 27.0% on the same quarter a year earlier. Net income was $15 million, down 37.3% on the year, and diluted earnings per share $0.05. The figures are the company's own, from the 10-Q it filed with the SEC on 4 November 2026.
Revenue
$275 million
+27.0% on the year · +4.4% on the quarter
Q3 FY2024Q3 FY2026
Operating margin
7.0%
15.1% a year earlier
Q3 FY2024Q3 FY2026
Net income
$15 million
-37.3% on the year
Q3 FY2024Q3 FY2026
Diluted EPS
$0.05
-37.5% on the year
Q3 FY2024Q3 FY2026
this quarterthe same quarter a year earlierHover a bar for its figure.
What management said
Guidance figures: 1 raised, 1 kept.
Revenue rose 27% year over year: Total revenue was $275.4 million, up $58.5 million or 27% from $216.8 million a year earlier, with molecular profiling services providing most of the increase.
Case volume and ASP drove molecular growth: Management attributed molecular profiling growth primarily to higher total clinical case volume and ASP improvements.
Operating expenses rose 42%: Operating expenses were $163.0 million, up $48.1 million or 42% from $114.9 million a year earlier.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
Q3 FY2026
Q2 FY2026
Q3 FY2025
On the quarter
On the year
Last 8 quarters
Operating cash flow
-22.2
28.5
62.4
Capital expenditure
17.5
22.1
7.1
-20.9%
+146.2%
Free cash flow
-39.7
6.4
55.3
Free cash flow margin
-14.4%
2.4%
25.5%
Cash from investing
-17.5
-122
-7.1
Cash from financing
14.2
-36.9
-21.1
Depreciation and amortisation
6.6
6.5
4.9
+1.5%
+34.7%
Share-based compensation
18.5
22.2
13.7
-16.7%
+35.5%
Buybacks
10.0
21.4
0.0
-53.1%
Diluted shares, weighted
295m
283m
297m
+4.3%
-0.7%
Shares outstanding at period end
287m
283m
282m
+1.5%
+1.6%
Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.
Balance sheet
$ million
Q3 FY2026
Q2 FY2026
Q3 FY2025
On the quarter
On the year
Last 8 quarters
Shareholders' equity
639
592
478
+8.1%
+33.7%
Redeemable equity
n/a
n/a
0.0
Debt
393
393
376
+0.1%
+4.6%
Operating lease liabilities
63.5
52.9
43.8
+20.0%
+44.8%
Other liabilities
160
192
86.5
-17.0%
+84.6%
Total liabilities and equity
1,256
1,230
985
+2.1%
+27.5%
Fixed assets
102
95.7
64.0
+6.9%
+59.8%
Goodwill
19.3
19.3
19.3
0.0%
0.0%
Investments
102
102
2.3
-0.1%
+4,392.0%
Cash and equivalents
667
693
753
-3.7%
-11.4%
Receivables
133
117
26.7
+14.1%
+399.4%
Other assets
231
203
119
+14.2%
+94.4%
Total assets
1,256
1,230
985
+2.1%
+27.5%
Questions
What was Caris Life Sciences' revenue in Q3 FY2026?
Caris Life Sciences (CAI) reported revenue of $275 million for Q3 FY2026, the quarter ended 30 September 2026, up 27.0% on the same quarter a year earlier.
How much did Caris Life Sciences earn in Q3 FY2026?
Net income for Q3 FY2026 was $15 million, down 37.3% on the year, and diluted earnings per share $0.05.
When did Caris Life Sciences report Q3 FY2026 results?
Caris Life Sciences filed its 10-Q for the quarter ended 30 September 2026 with the SEC on 4 November 2026.
Each quarter as filed, linked to its filing. Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.
10-Q for the period ended 30 September 2026, filed 4 November 2026: the filing.